Ironwood Pharmaceuticals (IRWD) Gross Margin (2013 - 2020)

Ironwood Pharmaceuticals has disclosed Gross Margin across 7 years of filings, most recently posting 99.23% for Q4 2020.

• Gross Margin for Q4 2020 came in at 99.23%, up 795.0% year-over-year; the trailing twelve-month figure through Dec 2020 was 99.19% (up 644.0% YoY), and the FY2020 annual result was 99.19%, up 477.0% from the prior year.
• Gross Margin came in at 99.23% for Q4 2020 at Ironwood Pharmaceuticals, down from 100.0% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2020 to a low of 10631.5% in Q4 2018.
• The 4-year median for Gross Margin is 95.61% (2018), against an average of 574.84%.
• Across the five-year window, Gross Margin slumped 1072196 bps in 2018 and soared 1072278 bps in 2019, its largest moves.
• Ironwood Pharmaceuticals' Gross Margin stood at 90.46% in 2017, then tumbled by 11852 bps to 10631.5% in 2018, then surged by 101 bps to 91.28% in 2019, then rose by 9 bps to 99.23% in 2020.
• The last three Gross Margin figures came in at 99.23% (Q4 2020), 100.0% (Q3 2020), and 100.0% (Q2 2020), per Business Quant data.